{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:36:22Z","timestamp":1707525382489},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,2]]},"DOI":"10.7759\/cureus.48141","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T08:18:32Z","timestamp":1698913112000},"source":"Crossref","is-referenced-by-count":0,"title":["Bisphosphonates and Atypical Femur Fractures: Is the Relationship Causal or Casual?"],"prefix":"10.7759","author":[{"given":"Rajeshwaree","family":"Bal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ratnakar","family":"Ambade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nihaal","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prateek","family":"Upadhyay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2011.01.014","article-title":"Pharmacology of bisphosphonates","volume":"49","author":"Cremers S","year":"2011","unstructured":"Cremers S, Papapoulos S. Pharmacology of bisphosphonates. Bone. 2011, 49:42-9. 10.1016\/j.bone.2011.01.014","journal-title":"Bone"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1916525","article-title":"Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates","volume":"383","author":"Black DM","year":"2020","unstructured":"Black DM, Geiger EJ, Eastell R, et al.. Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. N Engl J Med. 2020, 383:743-53. 10.1056\/NEJMoa1916525","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline","volume":"104","author":"Eastell R","year":"2019","unstructured":"Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2019, 104:1595-622. 10.1210\/jc.2019-00221","journal-title":"J Clin Endocrinol Metab"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2072","article-title":"Trends in fracture incidence: a population-based study over 20 years","volume":"29","author":"Amin S","year":"2014","unstructured":"Amin S, Achenbach SJ, Atkinson EJ, Khosla S, Melton LJ III. Trends in fracture incidence: a population-based study over 20 years. J Bone Miner Res. 2014, 29:581-9. 10.1002\/jbmr.2072","journal-title":"J Bone Miner Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.061113","article-title":"Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025","volume":"22","author":"Burge R","year":"2007","unstructured":"Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007, 22:465-75. 10.1359\/jbmr.061113","journal-title":"J Bone Miner Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/2040622315584114","article-title":"Atypical femoral fractures and bisphosphonate use: current evidence and clinical implications","volume":"6","author":"Saita Y","year":"2015","unstructured":"Saita Y, Ishijima M, Kaneko K. Atypical femoral fractures and bisphosphonate use: current evidence and clinical implications. Ther Adv Chronic Dis. 2015, 6:185-93. 10.1177\/2040622315584114","journal-title":"Ther Adv Chronic Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1610","article-title":"Atypical femur fractures: refining the clinical picture","volume":"27","author":"Abrahamsen B","year":"2012","unstructured":"Abrahamsen B. Atypical femur fractures: refining the clinical picture. J Bone Miner Res. 2012, 27:975-6. 10.1002\/jbmr.1610","journal-title":"J Bone Miner Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1719","article-title":"Incidence of atypical nontraumatic diaphyseal fractures of the femur","volume":"27","author":"Dell RM","year":"2012","unstructured":"Dell RM, Adams AL, Greene DF, et al.. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res. 2012, 27:2544-50. 10.1002\/jbmr.1719","journal-title":"J Bone Miner Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1550","article-title":"Incidence and demography of femur fractures with and without atypical features","volume":"27","author":"Feldstein AC","year":"2012","unstructured":"Feldstein AC, Black D, Perrin N, et al.. Incidence and demography of femur fractures with and without atypical features. J Bone Miner Res. 2012, 27:977-86. 10.1002\/jbmr.1550","journal-title":"J Bone Miner Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-008-0805-x","article-title":"Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study","volume":"20","author":"Lenart BA","year":"2009","unstructured":"Lenart BA, Neviaser AS, Lyman S, et al.. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int. 2009, 20:1353-62. 10.1007\/s00198-008-0805-x","journal-title":"Osteoporos Int"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2011.01.003","article-title":"Safety of bisphosphonates","volume":"49","author":"Pazianas M","year":"2011","unstructured":"Pazianas M, Abrahamsen B. Safety of bisphosphonates. Bone. 2011, 49:103-10. 10.1016\/j.bone.2011.01.003","journal-title":"Bone"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.injury.2007.08.036","article-title":"An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?","volume":"39","author":"Kwek EB","year":"2008","unstructured":"Kwek EB, Goh SK, Koh JS, Png MA, Howe TS. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?. Injury. 2008, 39:224-31. 10.1016\/j.injury.2007.08.036","journal-title":"Injury"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research","volume":"29","author":"Shane E","year":"2014","unstructured":"Shane E, Burr D, Abrahamsen B, et al.. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014, 29:1-23. 10.1002\/jbmr.1998","journal-title":"J Bone Miner Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S0020-1383(16)30015-8","article-title":"How do bisphosphonates affect fracture healing?","volume":"47","author":"Kates SL","year":"2016","unstructured":"Kates SL, Ackert-Bicknell CL. How do bisphosphonates affect fracture healing?. Injury. 2016, 47:S65-8. 10.1016\/S0020-1383(16)30015-8","journal-title":"Injury"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0601643103","article-title":"The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs","volume":"103","author":"Kavanagh KL","year":"2006","unstructured":"Kavanagh KL, Guo K, Dunford JE, et al.. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci U S A. 2006, 103:7829-34. 10.1073\/pnas.0601643103","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.12551","article-title":"Questioning the association between bisphosphonates and atypical femoral fractures","volume":"1335","author":"Pazianas M","year":"2015","unstructured":"Pazianas M, Kim SM, Yuen T, Sun L, Epstein S, Zaidi M. Questioning the association between bisphosphonates and atypical femoral fractures. Ann N Y Acad Sci. 2015, 1335:1-9. 10.1111\/nyas.12551","journal-title":"Ann N Y Acad Sci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2012.1796","article-title":"Increasing occurrence of atypical femoral fractures associated with bisphosphonate use","volume":"172","author":"Meier RP","year":"2012","unstructured":"Meier RP, Perneger TV, Stern R, Rizzoli R, Peter RE. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med. 2012, 172:930-6. 10.1001\/archinternmed.2012.1796","journal-title":"Arch Intern Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-018-0464-6","article-title":"Current understanding of epidemiology, pathophysiology, and management of atypical femur fractures","volume":"16","author":"Starr J","year":"2018","unstructured":"Starr J, Tay YK, Shane E. Current understanding of epidemiology, pathophysiology, and management of atypical femur fractures. Curr Osteoporos Rep. 2018, 16:519-29. 10.1007\/s11914-018-0464-6","journal-title":"Curr Osteoporos Rep"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.85a.17119","article-title":"Bisphosphonate-related atypical femoral fracture: managing a rare but serious complication","volume":"85","author":"Silverman S","year":"2018","unstructured":"Silverman S, Kupperman E, Bukata S. Bisphosphonate-related atypical femoral fracture: managing a rare but serious complication. Cleve Clin J Med. 2018, 85:885-93. 10.3949\/ccjm.85a.17119","journal-title":"Cleve Clin J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2011.03713.x","article-title":"Bisphosphonates and osteonecrosis of the jaw","volume":"59","author":"Shannon J","year":"2011","unstructured":"Shannon J, Shannon J, Modelevsky S, Grippo AA. Bisphosphonates and osteonecrosis of the jaw. J Am Geriatr Soc. 2011, 59:2350-5. 10.1111\/j.1532-5415.2011.03713.x","journal-title":"J Am Geriatr Soc"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1248\/yakushi.19-00125","article-title":"Basic studies on the mechanism, prevention, and treatment of osteonecrosis of the jaw induced by bisphosphonates. [Article in Japanese]","volume":"140","author":"Endo Y","year":"2020","unstructured":"Endo Y, Funayama H, Yamaguchi K, et al.. Basic studies on the mechanism, prevention, and treatment of osteonecrosis of the jaw induced by bisphosphonates. [Article in Japanese]. Yakugaku Zasshi. 2020, 140:63-79. 10.1248\/yakushi.19-00125","journal-title":"Yakugaku Zasshi"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14780","article-title":"Bisphosphonate nephropathy: a case series and review of the literature","volume":"87","author":"de Roij van Zuijdewijn C","year":"2021","unstructured":"de Roij van Zuijdewijn C, van Dorp W, Florquin S, Roelofs J, Verburgh K. Bisphosphonate nephropathy: a case series and review of the literature. Br J Clin Pharmacol. 2021, 87:3485-91. 10.1111\/bcp.14780","journal-title":"Br J Clin Pharmacol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz295","article-title":"Medical management of patients after atypical femur fractures: a systematic review and recommendations from the European Calcified Tissue Society","volume":"105","author":"van de Laarschot DM","year":"2020","unstructured":"van de Laarschot DM, McKenna MJ, Abrahamsen B, et al.. Medical management of patients after atypical femur fractures: a systematic review and recommendations from the European Calcified Tissue Society. J Clin Endocrinol Metab. 2020, 105:1682-99. 10.1210\/clinem\/dgz295","journal-title":"J Clin Endocrinol Metab"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.5041\/RMMJ.10259","article-title":"Atypical femur fractures in patients treated with bisphosphonates: identification, management, and prevention","volume":"7","author":"Bubbear JS","year":"2016","unstructured":"Bubbear JS. Atypical femur fractures in patients treated with bisphosphonates: identification, management, and prevention. Rambam Maimonides Med J. 2016, 7:e0032. 10.5041\/RMMJ.10259","journal-title":"Rambam Maimonides Med J"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1210\/er.2018-00001","article-title":"Atypical femur fractures: review of epidemiology, relationship to bisphosphonates, prevention, and clinical management","volume":"40","author":"Black DM","year":"2019","unstructured":"Black DM, Abrahamsen B, Bouxsein ML, Einhorn T, Napoli N. Atypical femur fractures: review of epidemiology, relationship to bisphosphonates, prevention, and clinical management. Endocr Rev. 2019, 40:333-68. 10.1210\/er.2018-00001","journal-title":"Endocr Rev"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X20916983","article-title":"Atypical femur fractures: current understanding and approach to management","volume":"12","author":"Tile L","year":"2020","unstructured":"Tile L, Cheung AM. Atypical femur fractures: current understanding and approach to management. Ther Adv Musculoskelet Dis. 2020, 12:1759720X20916983. 10.1177\/1759720X20916983","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-012-0129-9","article-title":"Bisphosphonate drug holiday: choosing appropriate candidates","volume":"11","author":"Ro C","year":"2013","unstructured":"Ro C, Cooper O. Bisphosphonate drug holiday: choosing appropriate candidates. Curr Osteoporos Rep. 2013, 11:45-51. 10.1007\/s11914-012-0129-9","journal-title":"Curr Osteoporos Rep"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s11420-015-9469-1","article-title":"Bisphosphonate treatment in osteoporosis: optimal duration of therapy and the incorporation of a drug holiday","volume":"12","author":"Villa JC","year":"2016","unstructured":"Villa JC, Gianakos A, Lane JM. Bisphosphonate treatment in osteoporosis: optimal duration of therapy and the incorporation of a drug holiday. HSS J. 2016, 12:66-73. 10.1007\/s11420-015-9469-1","journal-title":"HSS J"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-021-00660-4","article-title":"Bisphosphonate drug holidays in primary care: when and what to do next?","volume":"19","author":"Bauer DC","year":"2021","unstructured":"Bauer DC, Abrahamsen B. Bisphosphonate drug holidays in primary care: when and what to do next?. Curr Osteoporos Rep. 2021, 19:182-8. 10.1007\/s11914-021-00660-4","journal-title":"Curr Osteoporos Rep"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.1232","article-title":"Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study","volume":"174","author":"Bauer DC","year":"2014","unstructured":"Bauer DC, Schwartz A, Palermo L, et al.. Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study. JAMA Intern Med. 2014, 174:1126-34. 10.1001\/jamainternmed.2014.1232","journal-title":"JAMA Intern Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/184886-bisphosphonates-and-atypical-femur-fractures-is-the-relationship-causal-or-casual","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:08:16Z","timestamp":1707509296000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/184886-bisphosphonates-and-atypical-femur-fractures-is-the-relationship-causal-or-casual"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,2]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.48141","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,2]]}}}